A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Asian Subjects With T2DM and Inadequate Glycemic Control on Metformin and Saxagliptin (DS Navigation)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Dec 2018 Planned initiation date changed from 12 Dec 2018 to 28 Feb 2019.
- 13 Dec 2018 Planned End Date changed from 3 Sep 2020 to 1 Mar 2021.
- 13 Dec 2018 Planned primary completion date changed from 3 Sep 2020 to 1 Mar 2021.